Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Li



Author of

  • +

    P2.03a - Poster Session with Presenters Present (ID 464)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.03a-024 - The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis (ID 3956)

      14:30 - 14:30  |  Author(s): Y. Li

      • Abstract

      Background:
      This study was conducted to extract a specific conclusion about the clinical efficacy of paclitaxel liposome in non-small cell lung cancer (NSCLC).

      Methods:
      Pubmed, Embase and Chinese National Knowledge Infrastructure (CNKI) databases were searched for potential relevant articles. Relative risks (RRs) with 95% confidence intervals (CIs) represented the influences of paclitaxel liposome on the objective response rate (ORR), disease control rate (DCR) and adverse events. I2＞50% and P＜0.05 indicate significant heterogeneity. If there existed heterogeneity, then the random-effects model was used. Otherwise, the fixed-effects model was adopted. Sensitivity analysis was performed to test the robustness of overall results. Begg’s funnel plot and Egger’s linear regression test were used to evaluate the potential publication bias.

      Results:
      The results indicated that paclitaxel liposome could improve the ORR of NSCLC patients (RR=1.22, 95%CI=1.03-1.44). Moreover, we observed that paclitaxel liposome was related with enhanced DCR as well (RR=1.08, 95%CI=1.01-1.16). The influences of paclitaxel liposome on the occurrences of adverse events were analyzed. The outcome suggested that paclitaxel liposome could inhibit the occurrences of muscle pain during the therapy (RR=0.34, 95%CI=0.26-0.45). Besides, onset of rash could also be inhibit by paclitaxel liposome (RR=0.17, 95%CI=0.08-0.35). Sensitivity analysis indicated that the overall results were robust. The funnel plot seemed to be symmetry (P=0.669).

      Conclusion:
      Paclitaxel liposome is an effective anti-cancer drugs for NSCLC patients.